Organization | Xinxiang Medical University

Xinxiang Medical University Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3

Founded: Xinxiang China (1950)

Organization Overview

First Clinical Trial

2014

NCT02025036

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2024

Timeline

NOW

Now

Alternative names

Affiliated Hospital of Xinxiang Medical University, Henan province | First Affiliated Hospital of Xinxiang Medical University | First Affiliated Hospital Xi'an Medical University | The First Affiliated Hospital of Xinxiang Medical College | The First Affiliated Hospital of Xinxiang Medical University | Xinxiang medical university

Active Ingredients

Drugs in Phase 3 Trials (12)

arginine (2 trials)

capecitabine (xeloda) (2 trials)

docetaxel (taxotere) (2 trials)

furosemide (lasix) (1 trial)

glycyrrhizin (1 trial)

human choriogonadotropin alfa (hCG) (1 trial)

paclitaxel (taxol) (1 trial)

rc48-adc (1 trial)

spironolactone (aldactone) (1 trial)

trimetazidine (2 trials)

vinorelbine (navelbine) (1 trial)

vitamin c (1 trial)

Drugs in Phase 2 Trials (3)

atezolizumab (Tecentriq) (1 trial)

bevacizumab (avastin) (1 trial)

tislelizumab (1 trial)

Drugs in Phase 1 Trials (3)

autologous natural killer cells (1 trial)

cccr-nk92 cells (1 trial)

nkg2d-car-nk92 cells (1 trial)

Drugs in Other Trials (8)

heparin (liquaemin) (2 trials)

lactobacillus (1 trial)

nitroprusside (nipride) (2 trials)

sacubitril (Entresto) (1 trial)

sodium chloride (2 trials)

tirofiban (aggrastat) (2 trials)

tpdelansbsalbac (1 trial)

valsartan (diovan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 3)

Carcinoma, Hepatocellular (Phase 3)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Carcinoma, Squamous Cell (Phase 3)

Coronavirus Infections (Phase 1)

Esophageal Squamous Cell Carcinoma (Phase 3)

Lung Neoplasms (Phase 1)

Pneumonia (Phase 1)

Overview

Highest Phase: Phase 3
# of Trials: 14
# of Trial APIs: 26